Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2011
Subject: Entry into a Material Definitive Agreement regarding the distribution of Fluviral Influenza Vaccine.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a contractual amendment.
Material Changes
The Company entered into an amendment to its Distribution Agreement with ID Biomedical Corporation of Quebec (IDB) concerning the Fluviral Influenza Vaccine. Key changes include:
- Extension of Termination Window: The period during which IDB could terminate the agreement was extended from 15 days to 30 days following September 1, 2011.
- New Deadline: IDB may now provide written notice of termination on or before October 1, 2011.
- Automatic Termination: If IDB does not terminate the agreement by October 1, 2011, the Distribution Agreement will automatically terminate at the conclusion of the 2012/2013 Flu Season.
Outlook, Risks, and Management Commentary
Negotiation Status: The parties had failed to complete negotiations for the 2012/2013 Flu Season by the original September 1, 2011 deadline. The amendment was executed to allow additional time for these negotiations.
Contingencies: The continuation of the distribution relationship for the 2012/2013 Flu Season is contingent upon IDB not exercising its right to terminate by October 1, 2011. If no new agreement is reached and IDB does not terminate, the existing agreement expires after the 2012/2013 season.
Investor Verification Checklist
- Verify whether ID Biomedical Corporation of Quebec issues a termination notice by October 1, 2011.
- Confirm if a new definitive agreement for the 2012/2013 Flu Season is signed prior to the October 1, 2011 deadline.
- Assess the potential impact on revenue if the distribution agreement terminates at the conclusion of the 2012/2013 Flu Season.
- Review the full text of the Amendment attached as Exhibit 1.1 for specific terms not summarized in the 8-K.